Evidence map›Paper›PMID 35212915›Full record

Observational studyInternational journal of hematology2022

NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.

Wen-Li Hwang, Tsung-Chih Chen, Hsuan-Yu Lin, Ming-Chih Chang, Pei-Ching Hsiao, Li-Yuan Bai, Ching-Yuan Kuo, Yeu-Chin Chen, Ta-Chih Liu, Jyh-Pyng Gau and 15 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 12 institutions in 1 country.

Wen-Li HwangTaichung Veterans General Hospital, Taichung, Taiwan.
Tsung-Chih ChenTaichung Veterans General Hospital, Taichung, Taiwan.
Hsuan-Yu LinChanghua Christian Hospital, Changhua, Taiwan.
Ming-Chih ChangMackay Memorial Hospital, Taipei, Taiwan.
Pei-Ching HsiaoChung Shan Medical University Hospital, Taichung, Taiwan.
Li-Yuan BaiChina Medical University Hospital, Taichung, Taiwan.
Ching-Yuan KuoKaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Yeu-Chin ChenTri-Service General Hospital, Taipei, Taiwan.
Ta-Chih LiuKaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
Jyh-Pyng GauTaipei Veterans General Hospital, Taipei, Taiwan.
Po-Nan WangLinkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Wei-Shou HwangChung Shan Medical University Hospital, Taichung, Taiwan.
Ming-Chung KuoLinkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Chun-Yu LiuTaipei Veterans General Hospital, Taipei, Taiwan.
Yi-Chang LiuKaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
Ming-Chun MaKaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Nai-Wen SuMackay Memorial Hospital, Taipei, Taiwan.
Chuan-Cheng WangChanghua Christian Hospital, Changhua, Taiwan.
Yi-Ying WuTri-Service General Hospital, Taipei, Taiwan.
Ming YaoNational Taiwan University Hospital, Taipei, Taiwan.
Su-Peng YehChina Medical University Hospital, Taichung, Taiwan.
Hao-Wei ChengNovartis (Taiwan) Co. Ltd., Taipei, Taiwan.
Yee-Ming LeeNovartis (Taiwan) Co. Ltd., Taipei, Taiwan.
Fan-Chen KuNovartis (Taiwan) Co. Ltd., Taipei, Taiwan.
Jih-Luh TangNational Taiwan University Hospital, Taipei, Taiwan. tangntuh@gmail.com.ORCID http://orcid.org/0000-0003-4021-3281
Asia University · TWChanghua Christian Hospital · TWChina Medical University · TWKaohsiung Chang Gung Memorial Hospital · TWKaohsiung Medical University Chung-Ho Memorial Hospital · TWLinkou Chang Gung Memorial Hospital · TWMackay Memorial Hospital · TWNational Taiwan University Hospital · TWTaipei Veterans General Hospital · TWTri-Service General Hospital · TWChung Shan Medical University Hospital · TWTaichung Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nilotinib has been approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph

Indexed as

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukopeniaThrombocytopeniaHumansPhiladelphia ChromosomeProtein Kinase InhibitorsPyrimidinesTaiwanTreatment OutcomeAntineoplastic AgentsnilotinibProtein Kinase InhibitorsPyrimidinesChronic myeloid leukemiaFirst-line treatmentNilotinibReal-world setting

Identifiers

PMID35212915
OpenAlexW4214769469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.